Marker Therapeutics Inc., listed on NASDAQ as MRKR, has unveiled its latest corporate presentation highlighting the advancements in its MAR-T Cell Platform technology. Developed at Baylor College of Medicine, the MAR-T (Multi-Antigen Recognizing T cell) technology offers potential therapeutic and manufacturing benefits over traditional T cell therapies. Marker's lead product, MT-601, targets six tumor-specific antigens, positioning it for broad tumor recognition and treatment. The MT-601 has demonstrated durable objective response rates in a Phase 1 clinical trial for lymphoma patients who have relapsed after anti-CD19 CAR-T cell therapy or for whom CAR-T cell therapy is not viable. The company maintains a robust intellectual property position with FDA-cleared investigational new drug applications for three MAR-T based clinical programs. Marker Therapeutics continues to seek non-dilutive funding, having secured over $30 million to date. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the original content used to generate this news brief on August 26, 2025, and is solely responsible for the information contained therein.
Comments